Back to results
US 12,758,532 B2Granted
Substituted heteroaryl compounds and use thereof
AssigneeHelios Huaming Biopharma Co., Ltd.
InventorsYanming Wang, Yan Xia, Jinquan Sun, Mingde Xia
Life of this patent
Estimating the term…
Abstract
The present disclosure provides substituted heteroaryl compounds and use thereof, also provides compounds or pharmaceutically acceptable salts or solvates thereof as PAD inhibitors and their use in treatment of a disease or disorder.
Claims29
A compound of formula (I):
- wherein,
- X is halogen;
- W is C—R2;
- Y is O;
- Z is N;
- R3 is selected from (C6-C10) aryl, and (C1-C9) heteroaryl;
- R2 is independently selected from H, (C1-C8) alkyl, (C3-C10) cycloalkyl, (C6-C10) aryl, and (C1-C9) heteroaryl;
- R1 is independently selected from (C1-C8) alkyl, (C3-C10) cycloalkyl, (C6-C10) aryl, and (C1-C9) heteroaryl, provided that R1 and R2 are not bonded to one another by one or more chemical bonds;
- when R1 is (C3-C10) cycloalkyl or (C6-C10) aryl, said R1 is unsubstituted or substituted with one or more substituents R4, said R4 is independently selected from H, halogen, (C1-C8) alkyl, (C1-C8) haloalkyl, (C1-C8) alkoxy, (C1-C8) alkylamino,
- wherein, the asterisk “*” in the structure formulas indicates the available radical ends to be connected;
- when R3 is (C6-C10) aryl or (C1-C9) heteroaryl, said R3 is unsubstituted or substituted with one or more substituents R5, said R5 is independently selected from H, halogen, (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C1-C8) alkylamino, (C2-C9) heterocycloalkyl, (C6-C10) aryl, (C1-C9) heteroaryl,
- wherein, the asterisk “*” in the structure formulas indicates the available radical ends to be connected;
- when R5 is (C2-C9) heterocycloalkyl, (C6-C10) aryl or (C1-C9) heteroaryl, said R5 is unsubstituted or substituted with one or more substituents R6, said R6 is independently selected from H, halogen, (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) hydroxyalkyl;
- or a pharmaceutically acceptable salt or solvate thereof.
11 more elements
A compound of formula (II):
- wherein,
- X is halogen;
- W is C—R2;
- Y is O;
- Z is N;
- R3 is selected from (C6-C10) aryl, and (C1-C9) heteroaryl;
- R2 is independently selected from H, (C1-C8) alkyl, (C3-C10) cycloalkyl, (C6-C10) aryl, and (C1-C9) heteroaryl;
- R1 is independently selected from (C1-C8) alkyl, (C3-C10) cycloalkyl, (C6-C10) aryl, and (C1-C9) heteroaryl, provided that R1 and R2 are not bonded to one another by one or more chemical bonds;
- when R1 is (C3-C10) cycloalkyl or (C6-C10) aryl, said R1 is unsubstituted or substituted with one or more substituents R4, said R4 is independently selected from H, halogen, (C1-C8) alkyl, (C1-C8) haloalkyl, (C1-C8) alkoxy, (C1-C8) alkylamino,
- wherein, the asterisk “*” in the structure formulas indicates the available radical ends to be connected;
- when R3 is (C6-C10) aryl or (C1-C9) heteroaryl, said R3 is unsubstituted or substituted with one or more substituents R5, said R5 is independently selected from H, halogen, (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C1-C8) alkylamino, (C2-C9) heterocycloalkyl, (C6-C10) aryl, (C1-C9) heteroaryl
- wherein, the asterisk in the structure formulas indicates the available radical ends to be connected;
- when R5 is (C2-C9) heterocycloalkyl, (C6-C10) aryl or (C1-C9) heteroaryl, said R5 is unsubstituted or substituted with one or more substituents R6, said R6 is independently selected from H, halogen, (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) hydroxyalkyl;
- or a pharmaceutically acceptable salt or solvate thereof.
11 more elements
Dependencies are inferred from the claim text.